[Clinical implication of ischemic preconditioning in protection of reperfused tissues].
Ischemic preconditioning (IP), has emerged as a powerful experimental method of ameliorating ischemic-reperfusion injury in a variety of organs. Clinical trials using IP have been successfully carried out. They support the existence of IP induced cyto-protection in humans as well. IP induced "ischemia tolerance" and "reperfusion tolerance" mechanisms are presented. The new, recently discovered modifications of IP "remote preconditioning" and "postconditioning" and their possible clinical applications in the ischemia of human: heart, liver, lung, brain, kidney and skeletal muscles are discussed.
Drozdz
Włodzimierz
W
II Katedra Chirurgii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie. msdrozdz@cyf-kr.edu.pl
Sarwa
Aneta
A
Labza
Henryk
H
D000222:Adaptation, Physiological; D017209:Apoptosis; D015687:Cell Hypoxia; D002986:Clinical Trials as Topic; D006801:Humans; D019194:Ischemic Preconditioning; D007668:Kidney / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D015427:Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control*; D013514:Surgical Procedures, Operative / Q000379:methods